• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Apollomics Inc.

    11/1/24 4:10:57 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLM alert in real time by email
    6-K 1 d898189d6k.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of November 2024

    Commission file number: 001-41670

     

     

    Apollomics Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Not Applicable

    (Translation of registrant’s name into English)

    989 E. Hillsdale Blvd., Suite 220

    Foster City, California 94404

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒   Form 40-F ☐

     

     

     


    In connection with an Extraordinary General Meeting of Shareholders (the “Meeting”) of Apollomics Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Company”), the Company hereby furnishes the notice and proxy statement of the Meeting and the form of proxy card as Exhibits 99.1 and 99.2, respectively.

    Exhibits

     

    Exhibit

    No.

      

    Description

    99.1    Notice and Proxy Statement of the Meeting mailed to shareholders on November 1, 2024
    99.2    Form of Proxy Card mailed to shareholders on November 1, 2024

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

        Apollomics Inc.
    Date: November 1, 2024     By:  

    /s/ Guo-Liang Yu

         

    Guo-Liang Yu, Ph.D.

    Chief Executive Officer

     

    3

    Get the next $APLM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APLM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APLM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Apollomics Inc.

      SC 13D/A - Apollomics Inc. (0001944885) (Subject)

      8/15/24 4:38:25 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

      SC 13G/A - Apollomics Inc. (0001944885) (Subject)

      5/30/24 4:15:08 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Apollomics Inc. (Amendment)

      SC 13D/A - Apollomics Inc. (0001944885) (Subject)

      5/22/24 7:32:01 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLM
    Financials

    Live finance-specific insights

    See more
    • Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

      Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-

      3/28/24 7:00:00 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

      FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics' management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The conference call will be available on Apollomics' website, www.apollomicsinc.com, under the Investors section and will be archived there for approximately 90 days. The co

      3/26/24 8:00:00 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

      Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023; Cash runway to mid-year 2024 Debuted as a publicly traded targeted oncology company March 30, 2023 Management to host conference call Monday, October 2, 2023 at 8:30 a.m. ET FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today annou

      9/28/23 4:17:57 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

      Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for the vebreltinib development program, including in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification$9.8 million in cash and cash equivalents as of December 31, 2024, in conjunction with LaunXP upfront payment, pipeline focus and expense reductions expected to provide cash runway into the first quarter of 2026 FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics"), a late-stage clinical bio

      4/3/25 4:05:00 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

      LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer ("NSCLC")Apollomics to receive upfront payments of $10 million, and is eligible for pre-commercial milestones up to $50 million, and royalties on net product sales FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP International Co.,

      3/31/25 8:00:32 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

      FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan. The Phase 3 trial was a randomized, double-blinded bridging trial to evaluate the safety and efficacy of uproleselan administered with chemotherapy versus chemotherapy alone in patients with relapsed or refract

      12/20/24 8:00:00 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLM
    SEC Filings

    See more
    • SEC Form 20-F filed by Apollomics Inc.

      20-F - Apollomics Inc. (0001944885) (Filer)

      4/3/25 4:51:31 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Apollomics Inc.

      6-K - Apollomics Inc. (0001944885) (Filer)

      4/3/25 4:40:55 PM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Apollomics Inc.

      6-K - Apollomics Inc. (0001944885) (Filer)

      3/31/25 8:00:45 AM ET
      $APLM
      Biotechnology: Pharmaceutical Preparations
      Health Care